Breathlessness mystery: can a finger device predict side effects in myeloma treatment?
NCT ID NCT04827563
First seen Mar 05, 2026 · Last updated Jun 19, 2026 · Updated 14 times
Summary
This study aimed to find out why some multiple myeloma patients develop shortness of breath when taking the drug carfilzomib. Researchers used an FDA-approved finger device called EndoPAT to check blood vessel health and tracked symptoms through surveys. The study enrolled 50 adults with newly diagnosed or relapsed multiple myeloma who were already receiving carfilzomib. The goal was to gather information to better prevent this side effect in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOTOXICITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carfilzomib
What this could lead to
If successful, this could help doctors predict and prevent shortness of breath in multiple myeloma patients receiving carfilzomib.
What could go wrong
This is a small, terminated pilot study, so results may be limited. It does not test a new treatment, only gathers information.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.